{"id":61651,"date":"2025-07-29T01:03:35","date_gmt":"2025-07-28T23:03:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/"},"modified":"2025-07-29T01:03:35","modified_gmt":"2025-07-28T23:03:35","slug":"flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/","title":{"rendered":"Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer"},"content":{"rendered":"
\n

EVANSTON, Ill.–(BUSINESS WIRE)–Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines, today announced the appointment of Barry Labinger as Chief Executive Officer. With more than three decades of executive experience in the biopharmaceutical industry, Barry brings a proven track record of building and leading innovative life sciences organizations through critical phases of growth, development, and commercialization.<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\nBarry joins Flashpoint at a transformative time as the company advances its scientific platform toward key clinical milestones. He most recently served as President and CEO of Gilboa Therapeutics, where he led the development of a novel engineered T-cell platform for solid tumors. Prior to Gilboa, Barry served as CEO at Checkmate Pharmaceuticals, where he led the company\u2019s IPO and the advancement of its lead clinical cancer immunotherapy program into registrational trials. During his previous leadership positions, including those at Human Genome Sciences, Bristol Myers Squibb, and Abbott Laboratories, Barry established and led major collaborations with industry leaders and helped bring groundbreaking therapies to patients.<\/p>\n

\n\u201cWe are delighted to welcome Barry Labinger to Flashpoint. His track record and deep experience in the strategic, scientific, clinical and commercial aspects of innovative therapeutics companies make him the ideal CEO to lead the next stage of growth for our company and the application of our technology to address major patient needs,\u201d said Dr. Chad Mirkin, Co-Founder and Member of the Flashpoint Therapeutics Board of Directors. \u201cI\u2019d like to thank Dr. Adam Margolin, our founding CEO, for his contributions in establishing the foundation of Flashpoint.\u201d<\/p>\n

\n\u201cI am thrilled to join Flashpoint Therapeutics at this critical juncture. Its structural nanomedicine platform is built upon extraordinary science developed at the laboratories of Dr. Chad Mirkin at Northwestern University, and I am confident it will result in groundbreaking new therapies that will make a profound impact on patients’ lives,\u201d said Barry Labinger, CEO of Flashpoint Therapeutics. \u201cI\u2019m honored to lead this mission-driven team and work alongside world-class scientific founders and investors to bring new hope to patients and families.\u201d<\/p>\n

\nBarry earned both his MBA and BA from Northwestern University, with concentrations in marketing, finance, and economics. He has held senior leadership roles at Immunex, 3M Pharmaceuticals, Human Genome Sciences, Emergent BioSolutions, Bristol Myers Squibb, and Abbott Laboratories.<\/p>\n

\nAbout Flashpoint Therapeutics<\/b><\/p>\n

\nFlashpoint Therapeutics is a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines. Our platform enables the creation of targeted therapies that co-deliver optimized combinations of therapeutic components directly to individual cells, enhancing drug delivery, stability, potency, and safety. This modular approach supports a broad range of therapies, encompassing modalities like mRNA, DNA, proteins, and CRISPR. The company\u2019s proprietary discovery platform is founded on nanotechnology research developed over the past decade at the laboratory of Dr. Chad Mirkin, Director of the International Institute for Nanotechnology at Northwestern University. Through strategic licensing and acquisition transactions with Northwestern University, Holden Pharmaceuticals, and Exicure, Flashpoint has assembled more than 150 issued patents and patent applications covering nucleic acid, protein, and CRISPR gene editing therapeutics. The company is funded by key investors, including Beta Lab and CS Venture Opportunities Fund. The company has also established an important partnership with King Abdullah International Medical Research Center (KAIMRC), which will advance the technology platform via the Flashpoint-KAIMRC Center of Excellence in Structural Nanomedicine.<\/p>\n

\nFor more information about Flashpoint Therapeutics, please visit www.flashpoint.bio<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:
\n
Rosie Gonzalez
\n
+1 (847) 922-9385
\n
rosie@flashpoint.bio<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

EVANSTON, Ill.–(BUSINESS WIRE)–Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines, today announced the appointment of Barry Labinger as Chief Executive Officer. With more than three decades of executive experience in the biopharmaceutical industry, Barry brings a proven track record of building and leading innovative life sciences organizations through critical … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61651","6":"format-standard","7":"category-industry"},"yoast_head":"\nFlashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"EVANSTON, Ill.–(BUSINESS WIRE)–Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines, today announced the appointment of Barry Labinger as Chief Executive Officer. With more than three decades of executive experience in the biopharmaceutical industry, Barry brings a proven track record of building and leading innovative life sciences organizations through critical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-28T23:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250728524235\/en\/2536328\/22\/Barry.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer\",\"datePublished\":\"2025-07-28T23:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/\"},\"wordCount\":578,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728524235\\\/en\\\/2536328\\\/22\\\/Barry.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/\",\"name\":\"Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728524235\\\/en\\\/2536328\\\/22\\\/Barry.jpg\",\"datePublished\":\"2025-07-28T23:03:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728524235\\\/en\\\/2536328\\\/22\\\/Barry.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728524235\\\/en\\\/2536328\\\/22\\\/Barry.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer - Pharma Trend","og_description":"EVANSTON, Ill.–(BUSINESS WIRE)–Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines, today announced the appointment of Barry Labinger as Chief Executive Officer. With more than three decades of executive experience in the biopharmaceutical industry, Barry brings a proven track record of building and leading innovative life sciences organizations through critical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/","og_site_name":"Pharma Trend","article_published_time":"2025-07-28T23:03:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250728524235\/en\/2536328\/22\/Barry.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer","datePublished":"2025-07-28T23:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/"},"wordCount":578,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250728524235\/en\/2536328\/22\/Barry.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/","url":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/","name":"Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250728524235\/en\/2536328\/22\/Barry.jpg","datePublished":"2025-07-28T23:03:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250728524235\/en\/2536328\/22\/Barry.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250728524235\/en\/2536328\/22\/Barry.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/flashpoint-therapeutics-appoints-barry-labinger-as-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61651"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61651\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}